Latest news with #EuropeanGMP
Mint
28-05-2025
- Business
- Mint
Reliance Infra, Va Tech Wabag among 18 micro-cap stocks that surged up to 24% in a week amid stock market volatility
Microcap stocks in focus: Shares of Va Tech Wabag, Reliance Infrastructure, Refex Industries, Gopal Snacks, Prince Pipes & Fittings, Subros, and Neogen Chemicals are among 18 micro-cap stocks that defied market volatility to deliver double-digit gains over the past week. Despite the back-and-forth movement in frontline indices amid global headwinds—including rising trade tensions, US fiscal concerns, and higher bond yields—as well as positive domestic tailwinds such as reports of India becoming the fourth-largest economy, the RBI's bumper dividend, and a steady rise in the rupee, several often-overlooked micro-cap stocks have managed to shine amid ongoing market volatility. These stocks span sectors such as pharma, FMCG, industrials, utilities, chemicals & petrochemicals, and fertilisers. Some counters witnessed a spike in demand following the release of their March quarter results, while others rallied on the back of recent order wins and value buying at lower levels. The Nifty Microcap 250 index rose 2.33% over the past week and 9% over the past month, outperforming the Nifty 50, which gained 0.30% and 3% during the same periods. Shilpa Medicare's stock surged 24.3% over the past week, pushing its May gains to 36%, the highest monthly rise since February 2020. The rally is driven by multiple positive developments, including its subsidiary Shilpa Pharma Lifesciences receiving an EIR from the USFDA and its biologics arm obtaining European GMP certification for its Dharwad facility, with zero inspection observations. Dishman Carbogen Amcis is another stock from the pharma pack that maintained a steady upward trajectory, gaining 22.2% in a week. Enviro Infra Engineers' shares also jumped 20%, while those of Prince Pipes & Fittings, Sequent Scientific, Gopal Snacks, and Refex Industries delivered returns of up to 14%. Stock Name Returns in last one week Shilpa Medicare 24% Dishman Carbogen Amics 22.2% Enviro Infra Engineers 20% Prince Pipes & Fittings 17.3% Sequent Scientific 15.8% Gopal Snacks 14.4% Refex Industries 13.8% Va Tech Wabag 12.9% Subros 12% Venus Pipes & Tubes 11.9% Reliance Infrastructure 11.7% ITD Cementation India 11.4% ISGEC Heavy Engineering 10.8% Kaveri Seed Company 10.3% Neogen Chemicals 10.1% Transrail Lighting 10.1% India Glycols 10% Lloyds Enterprises 10% Source: Trendlyne On the back of steady order wins, coupled with a healthy performance in the March quarter, Va Tech Wabag's share price jumped 13% in a week. The Indian water treatment company has secured new orders worth roughly ₹ 57 billion this year, increasing its order book to around ₹ 137 billion, including framework agreements. Likewise, Reliance Infrastructure's share price also surged 12%. The company-promoted Reliance Defence and Düsseldorf-based Rheinmetall AG entered into a strategic partnership in the field of ammunition on May 22. This marks the third major partnership for Reliance Defence, following its successful strategic alliances with Dassault Aviation and the Thales Group of France, the company said in its May 23 press release. Dr. VK Vijayakumar, Chief Investment Strategist at Geojit Financial Services, said the market is likely to consolidate around current levels in the near term. With mutual funds holding sizeable cash reserves, any dip is expected to be bought into, while high valuations may lead to selling on rallies. He noted that a sustained rally will only occur once leading indicators point to a revival in earnings growth, which may take some time. Vijayakumar also highlighted a slow accumulation in rate-sensitive sectors like autos, driven by expectations of further rate cuts amid declining inflation. Additionally, he pointed out that investors are now staying invested through SIPs for longer periods than before, which is expected to provide underlying support to the market. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
Business Upturn
15-05-2025
- Business
- Business Upturn
Shilpa Medicare shares climb nearly 4% after USFDA EIR for subsidiary, gains European GMP nod for biologics unit
By Aditya Bhagchandani Published on May 15, 2025, 09:20 IST Shares of Shilpa Medicare rose 3.86% to ₹721.75 on the NSE in early trade on Wednesday after the company announced multiple regulatory approvals across its units. The stock opened at ₹701.20 and touched an intraday high of ₹729.45, driven by investor optimism around recent global clearances. The company disclosed that its subsidiary, Shilpa Pharma Lifesciences (Unit-1), received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) following an inspection conducted from March 3–7, 2025. The site was classified as Voluntary Action Indicated (VAI), indicating compliance with the agency's expectations. Additionally, Shilpa Biologics' manufacturing site in Dharwad, Karnataka, secured a European GMP certification earlier this month. The certification came after an inspection by the Austrian competent authority between February 18–20, 2025, which concluded with zero observations. In another strategic development, Shilpa Biologicals signed a binding term sheet with Switzerland-based mAbTree Biologics AG in March 2025 for the development, production, and commercialisation of a new biological entity (NBE). The stock currently trades near ₹721.75 with a market capitalization of ₹70,510 crore. It has seen a 52-week high of ₹959.50 and a low of ₹417.60, reflecting continued investor interest in the company's growing global footprint in both generics and biologics. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
05-05-2025
- Business
- Business Upturn
Shilpa Medicare shares jump 3% after arm gets EU GMP clearance for Dharwad plant
By Aman Shukla Published on May 5, 2025, 09:41 IST Shares of Shilpa Medicare rose 3% in early trade on Monday after its biologics division, Shilpa Biologics, received European GMP certification for its manufacturing site in Dharwad, Karnataka. At 9:40 AM, the shares were trading 2.94% higher at Rs 649.00. The certification follows a successful inspection by the Austrian competent authority, conducted from February 18 to 20, 2025. The inspection assessed the facility's sterile drug product filling and packaging line, quality systems, and quality control laboratories. The site was found compliant with the EU's Good Manufacturing Practice (GMP) standards as per Directive (EU) 2017/1572. This certification is a key regulatory milestone, allowing Shilpa Biologics to manufacture test batches for European markets—a crucial step toward expanding its global footprint. Commenting on the development, Dr. Sridevi Khambhampaty, CEO of Shilpa Biologics, said, 'This inspection outcome affirms our commitment to global quality standards and assures reliable outcomes for our customers.' Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
